ME/CFS Science @mecfsscience.org · 14/07/20265) This was a large placebo-controlled and international trial: it recruited 203 patients from three European countries (Switzerland, Italy, and Spain) involving 14 centers. The primary outcome was the PROMIS Fatigue SF 7a scale. 150
ME/CFS Science @mecfsscience.org · 14/07/20266) The main result is shown in the figure below. Temelimab had no effect on fatigue, and the same null results were seen for the secondary outcomes, including several cognitive tests and biomarkers. 160
ME/CFS Science @mecfsscience.org · 14/07/20267) The trial was sponsored by the Swiss biopharma company GeNeuro, which makes the drug. A couple of years ago, a randomized trial of Temelimab in multiple sclerosis also failed on its primary outcome. pubmed.ncbi.nlm.nih.... 150
